MASP2 and COVID-19: Interestingly, Narsoplimab, a fully humanized immunoglobulin gamma 4 (IgG4) monoclonal antibody against MASP-2 that inhibits LP functional activity, has been used successfully in treatment of critically ill, mechanical ventilation-dependent COVID-19 patients.